- Optimizing Patient Treatment With EPA-enriched Nutrition, a Randomised Control Trial — Recruiting • Non-phase study • Oncology • NCT07255066.
- Intervention tested: An EPA-enriched (eicosapentaenoic acid) nutritional intervention is being evaluated in a randomised controlled trial to address malnutrition in cancer patients, with the aim of improving weight maintenance, muscle strength, and overall nutritional status.
- Patient eligibility overview: The trial targets cancer patients experiencing malnutrition-related complications including weight loss and muscle weakness, who are at risk of treatment delays or reduced treatment efficacy due to poor nutritional status.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
Malnutrition is a common and serious issue for people living with cancer. Many cancer patients experience weight loss, muscle weakness, and poor quality of life due to malnutrition. This can also reduce the success of cancer treatments, increase hospital visits, and add emotional distress for both patients and their loved ones. Treating malnutrition through good nutritional care is increasingly recognised as an important part of cancer treatment. Leading experts recommend that all cancer patients be checked for signs of malnutrition and given personalised nutrition plans when necessary. While dietary counselling…
- : * Participants with stage III-IV lung and/or colorectal cancer undergoing systemic anti-cancer treatment (SACT) or starting SACT within the next 4 weeks *with non-curative intent * Participants aged 18 or older * Participants at nutritional risk defined as a BMI 10 mg/dL) * Participants with an ECOG-PS*** score of 0, 1 or 2 * Participants willing and able to give written informed consent
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.